



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/697,563

10/31/2003

Najla Guthrie

21055-77

8415

28221 7590 06/27/2008
PATENT DOCKET ADMINISTRATOR
LOWENSTEIN SANDLER PC
65 LIVINGSTON AVENUE
ROSELAND, NJ 07068

EXAMINER

BETTON, TIMOTHY E

ART UNIT

PAPER NUMBER

1617

MAIL DATE

DELIVERY MODE

06/27/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/697,563	Applicant(s) GUTHRIE ET AL.	
	Examiner TIMOTHY E. BETTON	Art Unit 1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 19 February 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 15,20-23 and 25-29 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 15,20-23 and 25-29 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Applicants' Remarks filed 19 February 2008 has been acknowledged and duly made of record.

The essence of applicants arguments are drawn to a lack of alleged combinability of the references. Applicant avers that the references as already made of record do not possess the motivation both separately or in combination due to what the applicant describes as different fields of endeavor.

The crux of applicant's claimed invention is what the applicant further describes as the use of an effective ratio of the five specifically claimed polymethoxyflavones to reduce serum insulin levels by 26%.

Applicants purport that even though the Malterud recites a list of virtually every element found in the peel of an orange as disclosed in the instant Remarks, but essentially does not provide the motivation to use an effective amount as disclosed. Nor does the reference, as explained by applicant, support or suggest the motivation to address the limitation as disclosed in claims 26 and 27. These two claims are drawn specifically to the limitation of a composition comprising or consisting essentially of nobiletin and tangeretin.

Accordingly, the Natarajan reference has been withdrawn.

Furthermore, applicant purport that the Pershadsingh and Robbins references in combination with the Manthey, Malterud, and Bok still lack recognizable reasoning to combine.

Applicant's arguments have been considered but are not found persuasive.

The 103 (a) as presented in the last action is proper.

Manthey, Malterud, Bok, Pershadsingh, and Robbins adequately encompass the subject matter and inventive objective of the claimed invention. Principally, the Malterud and Robbins references provide the substantiating motivation to combine the references. Both references properly and sufficiently encompass the polymethoxyflavones as disclosed in instant claim 15. Manthey et al. adequately teach the direct treatment of metabolic conditions such as Type 2 diabetes with the use of several polymethoxy flavones. Bok teaches a metabolic condition treatable with bioflavonoids. Pershadsingh teach the specific reaction of a bioflavonoid in conjunction with treatment to a metabolic condition such as insulin resistance.

Instant claims 26 and 27 are particularly of interest further due to the sole or essentially the sole administration of nobiletin and tangeretin. However, succinctly in each and every reference cited these two main polymethoxyflavone components are apparently common, abundant and well-known in the art as essentially hallmark polymethoxyflavones as extracted from the peelings of citrus fruits. In other words, nobiletin and tangeretin may always appear in polymethoxyflavone composition formulation because of their established origin and function in the art. Still further, in a majority of formulations of polymethoxyflavones, the presence of nobiletin and tangeretin is so common and does not seem to ever be absent when mentioned with other polymethoxyflavones. Thus, one may conclude that a formulation void of any other polymethoxyflavone besides nobiletin and tangeretin may be deficient in the way of addressing the limitations drawn to an effective ratio to reduce levels by at least about 26%.

Claim Rejection, 35 U.S.C. § 103(a)

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 15 and 20-23 and 25-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Malterud et al. (Inhibitors of 15-lipoxygenase from orange peel. J Agric Food Chem (2000 Nov); 48(11): 5576-80, printed page: 1, Abstract, lines 1-6 and lines 17-21) and Manthey et al. (USPN 6,184,246 B1) in view of Bok et al. (USPN 6,096,364).

Malterud et al. teach the complete list of polymethoxylated flavonoids as disclosed in instant claim 15, such as sinensetin, nobiletin, tangeretin, heptamethoxyflavone and tetramethylscutellarein (as disclosed in instant claim 15), which have been isolated from orange peel and collectively are inhibitors of 15 lipoxygenase (lines 1-6).

Malterud et al. further teaches that [these] orange peel constituents may counteract enzymatic lipid peroxidation processes catalyzed by 15-lipoxygenase in vitro (lines 17-21).

Thus, Malterud et al. teach inhibitors of lipoxygenase, which is connected to Type 2 diabetes, which is consequently the disease to which insulin resistance progresses. Specifically, increased production of 15-lipoxygenase adversely affects insulin resistant/Type 2 diabetic patients. Insulin resistance is normally a precursor adverse affect, which progresses into Type 2 diabetic patients.

Manthey et al. teach several polymethoxylated flavones comprising tangeretin, nobiletin, sinensetin and heptamethoxyflavone (with the exception of tetramethylscutellarein) and a practicing disclosure of dosing parameters (column 3, lines 42 – 54). Generally, the dose of the polymethoxylated flavones given in the methods of the present invention (i.e., the effective amount of a polymethoxylated flavone) are at a quantity that results in a reduction in the concentration or in vivo amount of cytokines (e.g., tumor necrosis factor, alpha. interleukin-10, macrophage inflammatory protein-1.alpha. and the like; especially tumor necrosis factor. alpha.) in the mammal. Preferably, the dose is a cytokine production-inhibiting amount (e.g., a quantity of polymethoxylated flavones capable of inhibiting the production of the cytokines or reducing the amount produced or the rate of production of the cytokines). Methods of determining the effective concentrations are well known in the art. For example, a person of ordinary skill in the art can easily extrapolate the effective concentrations as determined in vitro and apply it to living mammals to determine the effective concentrations in vivo. Likewise, the disclosure of 26% in instant claim 15 would thereby encompass and overcome subject claim by way of obviousness via necessity of extrapolation of effective concentrations to achieve claimed reduction of serum insulin levels. Preferably, the dose of the polymethoxylated flavone is between 0.1-10 grams per 100 Kg body weight; most preferably between 1-10 grams per 100 Kg body weight (column 4, lines 19 – 36). Instant claims 21 and 22 disclose a PMF composition of which up to 5000 mg/day may be administered and said composition being administered in a specific dosage of 70mg/kg/day, based on weight of said mammal, respectively. Accordingly, Manthey et al. teach the various administration routes of polymethoxylated flavones, such as oral, transdermal,

subcutaneous, rectal, intraarticular, intravenous and intramuscular introduction, that are obvious over instant claims 21 and 20, which disclose same routes for said agent.

Manthey et al. do not teach a method for preventing insulin resistance nor does it teach on tetramethylscutellarein, a polymethoxylated flavone as disclosed in instant claim 15.

Bok et al. teach a method for lowering blood glucose levels in diabetic patients by the administration of bioflavonoid. The polymethoxylated flavones taught are nobiletin, sinensetin, and tangeretin (column 1, Table I).

Bok et al. do not specifically teach a method of reducing insulin resistance nor does it teach on tetramethylscutellarein or heptamethoxyflavone as disclosed in instant claim 15.

Thus, it is prima facie obvious to combine and/or incorporate together the teachings of Malterud et al., Manthey et al., and Bok et al., via the motivation to combine by Malterud et al. Malterud et al. teach the complete disclosure of polymethoxylated flavones as disclosed in instant claim 15. As comprised in instant claim 15 for insulin resistance, the five disclosed polymethoxylated flavones are taught as a group comprising thereof for inhibition of 15-lipoxygenase. One of ordinary skill in the pertinent art at the time of the instant invention would instantly recognize the motivation to incorporate and modify the teachings of Manthey et al. and Bok et al. with the addition of Malterud et al. (incorporating the addition of tetramethylscutellarein). Accordingly, The radical –scavenging activity of the five instant polymethoxylated flavones disclosed results in a practicing method of reducing 15- lipoxygenase (Hatley et al. Increased production of 12/15 lipoxygenase eicosanoids accelerates monocyte/endothelial interactions in diabetic db/db mice. J Biol Chem. 2003 July 13; 278(28): 25369-75, printed pages 1 and 2, see page 1). One of ordinary skill in the pertinent art would

have had a reasonable expectation of successfully combining the method of Manthey et al. and the method of Bok et al., (as both teach the administration of polymethylated flavones (bioflavonoids)). Malterud et al. is the motivation to combine due to 1) the five identical bioflavonoid agents as disclosed and taught in instant invention and Malterud et al., and 2) the five identical bioflavonoid agents with indication of therapy for inhibiting an enzyme, which has direct correlation to insulin resistance as disclosed in instant invention. This rejection is necessitated by amendment.

Claim 25 is rejected under 35 U.S.C. 103(a) as being unpatentable over Malterud et al., Manthey et al., and Bok et al. as applied to claims 15 and 20-23 above, and further in view of Pershadsingh et al. (USPN 6,087,385) and Robbins (USPN 3,867,541).

Pershadsingh et al., teach tangeretin sensitizing and the reduction of insulin resistance (including diabetes) (Abstract, column 1, lines 20-40).

Pershadsingh et al. does not teach tangeretin or any other agents in its class as a single or combination therapy for insulin resistance. However, instant claim 25 discloses a polymethoxylated flavone composition comprising said agent or agents. Therefore, instant claim 25 suggests that the polymethoxyflavone composition could instantly comprise one said polymethoxyflavone and some other agent in order to mitigate insulin resistance.

Robbins teaches methoxylated flavonoids having at least two methoxyl radicals or substituents exhibiting powerful anti-adhesive effects on blood cells in vivo and in vitro. Such flavonoids are combined with an anticoagulant therefore providing greater protection against thrombi formation than when either is used without the other. Instant specification discloses an etiology of insulin resistance, which includes impairment of endothelium-dependent

Art Unit: 1617

vasodilation, and a reduction in nitric oxide, which is an important mediator involved in protection against atherosclerosis. Insulin resistance syndrome commonly precedes type 2 diabetes and both disorders are associated with the increased risk of heart disease (specification [0002] and [0003]). The teaching of Robbins overcomes instant claim 25 in the way of obviousness. Instant specification fails to disclose the reason of specificity in percentages of disclosed polymethoxylated flavones, however one of skill in the art would instantly recognize the necessity to extrapolate magnitudes for an efficacious therapeutic concentrations of components of said formulation.

Thus it would have been obvious to one of ordinary skill in the pertinent art at the time of the invention to have modified and/or combined the methods and teachings of Robbins and Pershadsingh et al. The instant invention is drawn toward a method of treating a mammal having metabolic abnormalities resulting from insulin resistance comprising administering an effective amount of polymethoxyflavone composition comprising sinensetin, nobiletin, tangeretin, heptamethoxyflavone and tetramethylscutellarein to reduce serum insulin levels by at least about 26% (instant claim 15). One of ordinary skill in the art would have had a reasonable expectation of successfully combining and/or modifying Robbins and Pershadsingh et al. which both essentially teach practicing polymethoxylated flavones and methods of administration thereof. This rejection is necessitated by amendment.

Further, in view of all references cited *supra*, the deficiencies of the Malterud et al. reference are adequately elucidated by Manthey et al. and Bok et al. Malterud et al adequately satisfy the deficiencies of Manthey et al. and Bok et al. Malterud et al. essentially teaches each

and every polymethoxyflavonoid in view of the instant invention. Further motivation to combine is contained in the following:

“It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art.” In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980)

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Timothy E. Betton whose telephone number is (571) 272-9922. The examiner can normally be reached on Monday-Friday 8:30a - 5:00p. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

Art Unit: 1617

USPTO Customer Service Representative or access to the automated information system, call
800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Shengjun Wang/

Primary Examiner, Art Unit 1617

TEB